ISRCTN11595117进行中（未招募）1 期
A Phase I/Ib study evaluating single-agent inavolisib and inavolisib plus atezolizumab in PIK3CA-mutated cancers
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Participants must be at least 18 years of age
- •2. Histologically or cytologically confirmed recurrent and/or metastatic HNSCC that has been previously treated with systemic therapy in the recurrent and/or metastatic setting
- •3. Documented positive or negative human papillomavirus (HPV) status as determined locally by p16 immunohistochemistry (IHC; preferred), in situ hybridization, and/or by polymerase chain reaction-based assay. Participants with either HPV-positive or HPV-negative status are eligible (unknown HPV status is not eligible)
- •4. Eligible participants must not be suitable for treatment with surgery and/or radiation
- •5. Confirmation of biomarker eligibility: Valid results from either central testing of blood or local testing of blood or tumour tissue documenting PIK3CA-mutated tumour status
- •6. Consent to provide fresh (preferred) or archival tumour tissue specimen
- •7. Negative hepatitis B surface antigen (HBsAg) and total hepatitis B core antibody (HBcAb) test or positive total HBcAb test followed by a negative hepatitis B virus (HBV) DNA at screening
- •8. Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening
- •9. Measurable disease per RECIST v1.1
- •10. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- •11. Life expectancy of =12 weeks
排除标准
- •1. Prior treatment with any phosphatidylinositol 3-kinase (PI3K), protein kinase B (AKT), or mammalian target of rapamycin (mTOR) inhibitor, or any agent whose mechanism of action is to inhibit the PI3K/AKT/mTOR pathway
- •2. Appropriate for treatment with surgery and/or radiation at the time of entry into the study, as per national or local treatment guidelines
- •3. Type II diabetes requiring ongoing systemic treatment at the time of study entry; or any history of Type I diabetes
- •4. Malabsorption syndrome or other condition that would interfere with enteral absorption
- •5. Known and untreated, or active central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control). Participants with a history of treated CNS metastases are eligible provided they meet specified criteria
- •6. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures twice per week or more frequently
- •7. Serious infection requiring IV antibiotics within 7 days prior to Day 1 of Cycle 1
- •8. Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of the need for such a vaccine during study treatment
- •9. Any concurrent ocular or intraocular condition (e.g., cataract or diabetic retinopathy) that, in the opinion of the investigator, would require medical or surgical intervention during the study period to prevent or treat vision loss that might result from that condition
- •10. Active inflammatory (e.g., uveitis or vitritis) or infectious (e.g., conjunctivitis, keratitis, scleritis, or endophthalmitis) conditions in either eye or history of idiopathic or autoimmune-associated uveitis in either eye
- •11. Requirement for daily supplemental oxygen
- •12. Symptomatic active lung disease, including pneumonitis
- •13. History of or active inflammatory bowel disease (e.g., Crohn’s disease or ulcerative colitis) or any active bowel inflammation (including diverticulitis)
- •14. Known Human Immunodeficiency Virus (HIV) infection
- •15. Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, metabolic, or infectious disease) or any other diseases, active or uncontrolled pulmonary dysfunction, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, that may affect the interpretation of the results, or that renders the participant at high risk from treatment complications
- •16. Chemotherapy, radiotherapy, or any other anti-cancer therapy within 2 weeks before enrolment
- •17. Investigational drug(s) within 4 weeks before enrolment
- •18. Unresolved toxicity from prior therapy, except for hot flashes, alopecia, and Grade = 2 peripheral neuropathy
- •19. History of other malignancy within 5 years prior to screening, with specified exceptions
- •20. History of or active clinically significant cardiovascular dysfunction
- •21. Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study)
- •22. Chronic corticosteroid therapy of =10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids or immunosuppressants for a chronic disease
- •23. Allergy or hypersensitivity to components of the inavolisib formulation
- •24. Treatment with strong CYP3
研究者
相似试验
进行中（未招募）
1 期
An Open-label, Single Agent, Phase I/II Trial Investigating the Safety and Efficacy of RVU120 (SEL120) in Patients with Relapsed / Refractory Metastatic or Advanced Solid Tumors - RVU120 Phase I/II Solid Tumor StudyEUCTR2020-005923-35-ESRyvu Therapeutics S.A.120
进行中（未招募）
1 期
RVU 120 (SEL120) to be tested in for treatment patients with solid tumors who have failed previous available standard therapyRelapsed / Refractory Metastatic or Advanced Solid TumorsMedDRA version: 21.0Level: LLTClassification code 10049280Term: Solid tumourSystem Organ Class: 100000004864EUCTR2020-005923-35-PLRyvu Therapeutics S.A.193
招募中
1 期
RVU 120 (SEL120) to be tested in for treatment patients with solid tumors who have failed previous available standard therapyRelapsed / Refractory Metastatic or Advanced Solid TumorsMedDRA version: 21.0Level: LLTClassification code: 10049280Term: Solid tumour Class: 10029104CTIS2024-515131-30-00Ryvu Therapeutics S.A.54
已完成
1 期
The effect of DSP-2230/placebo on renal functioISRCTN02543559Sunovion Pharmaceuticals Europe Ltd (UK)44
进行中（未招募）
1 期
A Randomized, Phase 2 Study of Single-agent Erlotinib versus Oral Etoposide in Patients with Recurrent or Refractory Pediatric Ependymoma - PETEYEUCTR2009-016836-11-GBOSI Pharmaceuticals LLC25